#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Journal of Czech Physicians / 2020 - 7-8

Principles and new perspectives in the vaccination against SARS-CoV-2 virus

Czech version

Authors: Jitka Smetanová;  Zuzana Střížová;  Jiřina Bartůňková;  Tomáš Milota
Authors‘ workplace: Ústav imunologie 2. LF UK a FN Motol v Praze
Published in: Čas. Lék. čes. 2020; 159: 298-302
Category: Review Article

Overview

It has been a year since the first person on Earth became infected with a new type of coronavirus SARS-CoV-2, causing infectious acute respiratory disease COVID-19 with relatively high morbidity and mortality. The most endangered population by coronavirus SARS-CoV-2 are healthcare professionals, the elderly and people with associated comorbidities. Due to the fast community spread, governments of different European countries introduced precaution measures including limited socializing of people, closing of most public services and introducing mandatory facial protection.

The hope for a return to the life before the pandemic is the development of an effective and safe vaccine against SARS-CoV-2 which would presumably reduce the incidence of severe forms of COVID-19 and prevent the massive spread of the disease. At the end of November, we have 13 clinical trials in phase III involving SARS-CoV-2 vaccines based on inactivated viruses, recombinant non-pathogenic viral vectors and proteins. The first mRNA-based vaccine is currently being evaluated in phase II/III clinical trial and is already being distributed and applied to high-risk population in the United Kingdom, the United States, and Israel, followed by the countries of the European Union, including the Czech Republic.

In the review article we present currently ongoing clinical studies with a special focus on the phase III clinical trials and discuss the mechanisms of action of each type of vaccine.

Keywords:

COVID-19 – SARS-CoV-2 – Vaccines – clinical trials

Sources
  1. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
  2. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91: 157–160.
  3. Kim GU, Kim MJ, Ra SH et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect 2020; 26: 948.e1–948.e3.
  4. Gonçalves RSG, Victor AC, Tavare ACOC, Duarte ALBP. Be-careful! Behind the storm of severe COVID-19, could be hidden macrophage activation syndrome. A case report with excellent outcome. Research Square 2020, doi: 10.21203/rs.3.rs-47499/v1.
  5. Li X, Xu S, Yu M et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146: 110–118.
  6. Long QX, Tang XJ, Shi QL et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26: 1200–1204.
  7. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. WHO, 2020. Dostupné na: https://covid19.who.int
  8. Zaki AM, van Boheemen S, Bestebroer TM et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814–1820.
  9. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69: 635–664.
  10. Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology 2003; 8: S9–S14.
  11. Zhou H, Chen X, Hu T et al. A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein. Curr Biol 2020; 30: 2196–2203.e3.
  12. Lam TTY, Jia N, Zhang YW et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 2020; 583: 282–285.
  13. Zhang T, Wu Q, Zhang Z. Pangolin homology associated with 2019-nCoV. bioRxiv 2020, doi: 10.1101/2020.02.19.950253.
  14. Ou X, Liu Y, Lei X et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020; 11: 1–12.
  15. Zou X, Chen K, Zou J et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020; 14: 185–192.
  16. Chan JFW, Kok KH, Zhu Z et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9: 221–236.
  17. Pačes J, Střížová Z, Smrž D, Černý J. COVID-19 and the immune system. Physiol Res 2020; 69: 379–388.
  18. Koirala A, Joo YJ, Khatami A et al. Vaccines for COVID-19: The current state of play. Paediatr Respir Rev 2020; 35: 43–49.
  19. Parry J. China coronavirus: cases surge as official admits human to human transmission. BMJ 2020; 368: m236.
  20. Střížová Z, Bartůňková J, Smrž D. Can wearing face masks in public affect transmission route and viral load in covid-19? Cent Eur J Public Health 2020; 28: 161–162.
  21. Ren SY, Wang WB, Hao YG et al. Stability and infectivity of coronaviruses in inanimate environments. World J Clin Cases 2020; 8: 1391–1399.
  22. Savvides C, Siegel R. Asymptomatic and presymptomatic transmission of SARS-CoV-2: a systematic review. medRxiv 2020, doi: 10.1101/2020.06.11.20129072v2.
  23. van Doremalen N, Bushmaker T, Morris DH et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564–1567.
  24. Wang K, Long QX, Deng HJ et al. Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Clin Infect Dis 2020, doi: 10.1093/cid/ciaa1143.
  25. Kaushal N, Gupta Y, Goyal M et al. Mutational frequencies of SARS-CoV-2 genome during the beginning months of the outbreak in USA. Pathogens 2020; 9: 565.
  26. Lyons DM, Lauring AS. Mutation and epistasis in influenza virus evolution. Viruses 2018; 10: 407.
  27. Lorenc T, Marshall D, Wright K et al. Seasonal influenza vaccination of healthcare workers: systematic review of qualitative evidence. BMC Health Serv Res 2017; 17: 732.
  28. National Library of Medicine, the U.S. National Institutes of Health. ClinicalTrials.gov.
  29. Nishikawa H, Shiku H. DNA vaccine. Nihon Rinsho 2008; 66: 1867–1872.
  30. Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 2016; 15: 313–329.
  31. Kowalczyk DW, Ertl HCJ. Immune responses to DNA vaccines. Cell Mol Life Sci 1999; 55: 751–770.
  32. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines-a new era in vaccinology. Nat Rev Drug Discov 2018; 17: 261–279.
  33. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol 2019; 10: 594.
  34. Mahase E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ 2020; 371: m4471.
  35. Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines (Basel) 2014; 2: 624–641.
  36. Ramezanpour B, Haan I, Osterhaus A, Claassen E. Vector-based genetically modified vaccines: exploiting Jenner’s legacy. Vaccine 2016; 34: 6436–6448.
  37. Thacker EE, Timares L, Matthews QL. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines 2009; 8: 761–777.
  38. Chang S, Warner J, Liang L, Fairman J. A novel vaccine adjuvant for recombinant flu antigens. Biologicals 2009; 37: 141–147.
  39. Nascimento IP, Leite LCC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res 2012; 45: 1102–1111.
  40. Bell BP. Hepatitis A vaccine. Semin Pediatr Infect Dis 2002; 13: 165–173.
  41. Tillett RL, Sevinsky JR, Hartley PD et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis 2021; 21: 52–58.
  42. Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res 2020; 288: 198114.
  43. Swann OV, Holden KA, Turtle L et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020; 370: 5.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist
Crucial moments in Czechoslovak radiobiology history
Biological effects of ionizing radiation
Modern trends in radiotherapy
DNA repair in head and neck tumor cells and possibilities of its monitoring to estimate individual tumor radioresistance and selection of optimal primary treatment
Trends in pharmacological stimulation of regeneration of ionizing radiation-damaged mammalian organism
Biological dosimetry and modern (-omic) methods
Advances in research of DNA damage and repair in cells exposed to various types of ionizing radiation in the era of super-resolution optical microscopy
Úvodem
Editorial
Age is not a disease: Evolution of protective antibodies against SARS-CoV-2 in seniors from the Břevnice nursing home
Season of the year, vitamin D and COVID-19
Article was published in

Journal of Czech Physicians

Issue 7-8
2020 Issue 7-8
Download issue PDF
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#